Policymakers should break with drug and biotech norms and apply risk-based portfolio simulations to understand the global portfolio of COVID-19 vaccines.
Jack Scannell
Advertisement
Articles by Jack Scannell
Advertisement
Latest Updated Articles
COVID-19 Vaccines: Tool to Predict and Manage Global Portfolio Productivity and RiskPublished: April 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
2
Reducing Site Burden Through Better Technology Integration in Clinical Trials
3
ACT Brief: AI, Equity, and Innovation Drive Clinical Research Forward
4
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
